Filling the gap between guidelines and clinical practice in heart failure treatment — Still a far cry from reality

[1]  M. Komajda,et al.  Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey , 2007, European journal of heart failure.

[2]  A. Cohen-Solal,et al.  Heart failure due to left ventricular systolic dysfunction: treatment at discharge from hospital and at one year. , 2005, International journal of cardiology.

[3]  A. Hoes,et al.  [Guidelines for the Diagnosis and Treatment of Chronic Heart Failure: executive summary (update 2005)]. , 2005, Revista espanola de cardiologia.

[4]  P. Poole‐Wilson,et al.  Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey , 2005 .

[5]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[6]  A. Cohen-Solal,et al.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). , 2005, European heart journal.

[7]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[8]  N. Freemantle,et al.  The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. , 2003, European heart journal.

[9]  N. Freemantle,et al.  The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment , 2003 .

[10]  P. Macdonald,et al.  Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[11]  N. Freemantle,et al.  Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey , 2002, The Lancet.

[12]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[13]  A. Cohen-Solal.  [Management of heart failure by general practitioners in France. Results of the study IMPROVEMENT of heart failure (IMPROVEMENT-HF)]. , 2002, Archives des maladies du coeur et des vaisseaux.

[14]  K. Swedberg,et al.  Comprehensive guidelines for the diagnosis and treatment of chronic heart failure Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology , 2002, European journal of heart failure.

[15]  A. Cohen-Solal,et al.  [Registry of cardiac insufficiency in cardiology]. , 2001, Archives des maladies du coeur et des vaisseaux.

[16]  K. Swedberg,et al.  Guidelines for the diagnosis and treatment of chronic heart failure. , 2001, European heart journal.

[17]  E. Vicaut,et al.  Ambulatory heart failure management in private practice in France , 2001, European journal of heart failure.

[18]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[19]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[20]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[21]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[22]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[23]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[24]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[25]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[26]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[27]  H. Strömer,et al.  Adherence to guidelines is a predictor of outcome in chronic heart failure: the Mahler survey. , 2006, European heart journal.

[28]  A. Cohen-solal.  Prise en charge de l'insuffisance cardiaque par les médecins généralistes en France : Résultats de l'étude IMPROVEMENT of Heart Failure (IMPROVEMENT-HF) , 2002 .